Original Research
Published on 17 Oct 2025
Analysis of the twelve cases of immune-related myocarditis caused by cadonilimab
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1671973
- 264 views
Type at least 3 characters
1,508 articles
Original Research
Accepted on 16 Oct 2025
Transcriptomic Analysis Reveals TME-Mediated Macrophage IFIT1 Upregulation and CX3CR1 Suppression Drive Osteosarcoma Progression
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1686854
- 187 views
Case Report
Accepted on 16 Oct 2025
IL-6 Suppression: a Potential Strategy for Mitigating Severe Immune-Related Adverse Events in Nivolumab and Ipilimumab Therapy for Malignant Pleural Mesothelioma
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1671503
- 144 views
Case Report
Accepted on 16 Oct 2025
Dual Checkpoint Inhibition with Bevacizumab Yields Dramatic Response in Synchronous Double Primary HCC and ICC with Lung Metastasis
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1670818
- 107 views
Mini Review
Accepted on 16 Oct 2025
Decoding the Immune Microenvironment in Osteosarcoma: New Insights into Checkpoints, Vaccines, and CAR-T Cells
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1702219
Case Report
Published on 16 Oct 2025
Case Report: Diagnosis and treatment of giant thoracodorsal liposarcoma
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1570796
- 894 views
Mini Review
Accepted on 14 Oct 2025
Integrated Molecular and Microenvironmental Drivers of Drug Resistance in Gastrointestinal Cancers: Mechanisms, Immunotherapy Challenges, and Precision Strategies
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1675745
- 133 views
Case Report
Accepted on 14 Oct 2025
Complete Response of Advanced HER2-Amplified Lung Adenocarcinoma to Cadonilimab Combined with Disitamab Vedotin: A Case Report
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1587210
Original Research
Published on 14 Oct 2025
The role of immune- and lipid metabolism-related genes in macrophage polarization and prognosis of glioblastoma
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1660754
- 890 views
Systematic Review
Accepted on 10 Oct 2025
Navigating the Risks: A systematic review of immune checkpoint inhibitor therapy before liver transplant for hepatocellular carcinoma and its impact on allograft rejection and survival outcomes
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1689820
- 238 views
Case Report
Published on 10 Oct 2025
Immune-mediated gastritis in a patient with breast cancer due to therapy with immune checkpoint inhibitor pembrolizumab: a case report
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1624185
- 463 views
Original Research
Published on 10 Oct 2025
Treatment experience in managing severe immune-mediated hepatotoxicity induced by immune checkpoint inhibitors
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1657332
- 1,507 views
Original Research
Published on 10 Oct 2025
Dextran sulfate inhibits the invasion, migration, and programmed death-ligand 1 expression in human gastric cancer cells by affecting the M2 tumor-associated macrophage polarization
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1689053
- 495 views
Systematic Review
Accepted on 09 Oct 2025
The Effect of Traditional Chinese Medicine on Patients Undergoing Targeted Therapy for Liver Cancer: A Systematic Review and Meta-Analysis
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1674965
- 168 views
Original Research
Published on 09 Oct 2025
Blood-derived ratio indexes associated with severity and prognosis of immune checkpoint inhibitor-related cardiotoxicity: a retrospective analysis
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1676806
- 1,017 views
Original Research
Published on 09 Oct 2025
Ferroptosis’s Master Switch GPX4 emerges as universal biomarker for precision immunotherapy: a pan-cancer study with in vitro experiments validation
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2025.1643235
- 676 views